Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
BACKGROUND: Somatostatin analogs (SA) have been used for over 25 years in the treatment of acromegaly. A major disadvantage is the need to continue therapy indefinitely. OBJECTIVE: To evaluate the feasibility of discontinuing therapy in well-controlled patients with acromegaly treated chronically w...
Main Authors: | Ramírez, C, Vargas, G, González, B, Grossman, A, Rábago, J, Sosa, E, Espinosa-de-Los-Monteros, A, Mercado, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
by: Turner, H, et al.
Published: (1999) -
Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
by: Turner, H, et al.
Published: (1999) -
Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
by: Turner, H, et al.
Published: (2004) -
EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH LUNG CARCINOIDS
by: Granberg, D, et al.
Published: (2014) -
Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
by: I. A. Ilovayskaya
Published: (2022-06-01)